

Our pipeline

PROJECT	DESCRIPTION	INDICATIONS	PARTNERS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING	REGIONS
Delgocitinib ¹ LP0133	Topical pan-JAK inhibitor	Chronic hand eczema	JT						Global
		Palmoplantar Pustulosis							Global
Calcipotriol LP0053	Calcipotriene and betamethasone dipropionate foam	Plaque Psoriasis	LEO Pharma						China ²
Tralokinumab ³ LP0162	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)	AstraZeneca						Global
		Atopic Dermatitis (AD on hands)							Global
Temtokibart LP0145	Anti-IL-22RA1 monoclonal antibody	Atopic Dermatitis	argenx						Global
IL-1RAcP LP0189	Anti-IL-1RAcP monoclonal antibody	Inflammatory skin diseases	MorphoSys						Global
STAT6 ⁴	Oral program	Inflammatory diseases	Gilead						Global
Topical STAT6 ⁵ LP0208	Topical program	Inflammatory skin diseases							Global

¹ Approved in the EU, UK, Switzerland and the UAE for Chronic Hand Eczema

² Approved in e.g. the EU and U.S. for plaque psoriasis.

³ Approved in e.g. the EU and U.S. for atopic dermatitis in adults and adolescents.

⁴ Partnership announced 11 January 2025: Gilead controls the global rights to oral STAT6 program and are in full control of the clinical development. LEO Pharma will have the option to co-commercialize oral programs for dermatology ex-US.

⁵ LEO Pharma holds an exclusive license from Gilead for STAT6 topical products.